Prime Medicine launches with gene editing technology

By The Science Advisory Board staff writers

July 13, 2021 -- Prime Medicine has launched with $315 million in financing to rapidly advance its prime editing gene editing technology.

Prime editing acts like a DNA word processor to "search and replace" disease-causing genetic sequences at their precise location in the genome, without resulting in double-stranded DNA breaks that cause unwanted cellular changes.

The company is currently using prime editing to advance multiple drug discovery programs targeted at liver, eye, ex vivo hematopoietic stem cell, and neuromuscular indications.

Prime Medicine has secured $115 million in series A funding in addition to support with $200 million in series B financing approximately nine months after the company began operations.

Furthermore, Prime Medicine and Beam Therapeutics have built a partnership to form a collaborative approach to fighting diseases and accelerate the development of Prime editing to deliver therapies for patients. In the areas of partnership, Prime Medicine and Beam share research, expertise, and intellectual property for assays, know-how, delivery, and manufacturing.

The Broad Institute of MIT and Harvard (where the technology was developed) has extended a license for prime editing technology to Prime Medicine for human therapeutic uses under the Broad Institute's inclusive innovation model.

By the end of 2021, Prime Medicine plans to employ more than 100 full-time employees.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here